Sleuth’s knowledge base aggregates data from the registries, regulators, journals, companies, and banks that publish it, including coverage in China. Every source is listed below.
Sleuth covers the public data your database has, plus the sell-side research, China coverage, and proprietary signals it doesn’t.
Registries, regulators, journals, and company filings across the US, Europe, and Asia, collected from the source and kept current.
Sell-side research from banks and brokers, included in every plan, searchable next to everything else, and ready to use in your own analysis.
Our China coverage spans registries, regulators, exchanges, and broker research, translated so Chinese programs show up in the same search as everyone else’s.
Sleuth tracks which targets and indications are gaining attention across the bioeconomy, from signals only Sleuth has.
Every drug, trial, target, and company is matched across its sources and linked to its deals and documents, so one question reaches all of it. Studio, AI tools like Claude, and our team all work from the same knowledge base.
150K+
Every program by target, modality, and phase, with catalysts and sales forecasts.
1M+
From 20 registries, each linked to its drugs, sponsors, sites, and results.
500K+
Biological targets across every major therapeutic area, reconciled to one dictionary.
400K+
Public and private, with pipelines, deals, financings, and Chinese and English names.
200K+
Licensing, M&A, collaborations, and financings, with upfronts, milestones, and royalties where disclosed.
5M+
300K+
5M+
500K+